TABLE 2.
Characteristics and resistance phenotypes of the 19 BSI isolates
| Isolate no. | Isolation date (month/yr) | Phenotypea | PFGE | ST | MIC (μg/ml)b |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WGS | COL | TIGE | AK | CN | CIP | AMC | CAZ | CTX | FEP | TZP | SXT | IMI | ERT | MEM | FOSF | CHLOR | |||||
| K1 | 8/14 | PDR | A | 147 | Yes | >8 | 4 | >32 | >8 | >4 | >32 | >16 | >4 | >8 | >64 | >8 | 8 | >4 | 32 | >64 | >128 |
| K2 | 8/14 | PDR | A | 147 | Yes | >8 | 4 | >32 | >8 | >4 | >32 | >16 | >4 | >8 | >64 | >8 | 8 | >4 | 32 | 64 | >128 |
| K3 | 10/14 | PDR | A | 147 | Yes | >8 | 4 | >32 | >8 | >4 | >32 | >16 | >4 | >8 | >64 | >8 | 16 | >4 | 32 | 64 | >128 |
| K4 | 10/14 | PDR | A | 147 | Yes | 8 | 4 | >32 | >8 | >4 | >32 | >16 | >4 | >8 | >64 | >8 | 8 | >4 | >32 | >64 | >128 |
| K5 | 2/15 | XDR | B | 101 | Yes | >8 | 0.5 | 8 | >8 | >4 | >32 | >16 | >4 | >8 | >64 | >8 | 8 | >4 | 8 | 16 | 16 |
| K6 | 6/15 | XDR | B | 101 | No | >8 | 4 | 16 | >8 | >4 | >32 | >16 | >4 | >8 | >64 | >8 | 8 | >4 | 16 | 32 | 32 |
| K7 | 2/15 | XDR | B | 101 | No | >8 | 1 | 8 | >8 | >4 | >32 | >16 | >4 | >8 | >64 | >8 | 8 | >4 | 32 | ≤8 | 16 |
| K8 | 5/15 | XDR | B | 101 | No | >8 | 4 | 8 | >8 | >4 | >32 | >16 | >4 | >8 | >64 | >8 | 4 | >4 | 16 | ≤8 | >128 |
| K9 | 3/15 | XDR | B | 101 | Yes | >8 | 0.5 | 8 | >8 | >4 | >32 | >16 | >4 | >8 | >64 | >8 | 8 | >4 | 16 | 32 | 16 |
| K10 | 7/15 | XDR | B | 101 | Yes | >8 | 0.5 | 8 | 1 | >4 | >32 | >16 | >4 | >8 | >64 | >8 | 8 | >4 | 32 | 32 | 32 |
| K11 | 9/15 | XDR | B | 101 | No | >8 | 0.5 | 8 | >8 | >4 | >32 | >16 | >4 | >8 | >64 | >8 | 8 | >4 | 16 | 16 | 16 |
| K12 | 11/15 | XDR | B | 101 | No | >8 | 0.5 | 16 | >8 | >4 | >32 | >16 | >4 | >8 | >64 | >8 | 32 | >4 | >32 | 16 | 16 |
| K13 | 9/15 | XDR | B | 101 | Yes | >8 | 4 | 8 | >8 | >4 | >32 | >16 | >4 | >8 | >64 | >8 | 4 | >4 | 16 | 32 | 32 |
| K14 | 12/15 | XDR | B | 101 | No | >8 | 0.5 | 16 | >8 | >4 | >32 | >16 | >4 | >8 | >64 | >8 | 16 | >4 | 32 | 16 | 16 |
| K15 | 12/15 | XDR | B | 101 | No | >8 | 0.5 | 16 | >8 | >4 | >32 | >16 | >4 | >8 | >64 | >8 | 4 | >4 | 16 | ≤8 | 16 |
| K16 | 1/16 | XDR | B | 101 | No | >8 | 4 | 16 | >8 | >4 | >32 | >16 | >4 | >8 | >64 | >8 | 16 | >4 | 32 | 16 | >128 |
| K17 | 2/16 | XDR | B | 101 | No | >8 | 4 | 16 | >8 | >4 | >32 | >16 | >4 | >8 | >64 | >8 | 8 | >4 | 32 | 16 | >128 |
| K18 | 4/16 | XDR | B | 101 | Yes | >8 | 4 | 16 | >8 | >4 | >32 | 1 | >4 | 4 | >64 | >8 | 16 | >4 | >32 | 32 | >128 |
| K19 | 7/16 | XDR | B | 101 | Yes | >8 | 4 | 8 | >8 | >4 | >32 | 1 | 4 | 8 | >64 | >8 | 8 | >4 | >32 | 64 | >256 |
a
PDR, pandrug resistant; XDR, extensively drug resistant.
b
COL, colistin; TIGE, tigecycline; AK, amikacin; CN, gentamicin; CIP, ciprofloxacin; AMC, amoxicillin-clavulanate; CAZ, ceftazidime; CTX, cefotaxime; FEP, cefepime; TZP, piperacillin-tazobactam; SXT, trimethoprim-sulfamethoxazole; IMI, imipenem; ERT, ertapenem; MEM, meropenem; FOSF, fosfomycin; CHLOR, chloramphenicol.